The importance of being first: evidence from Canadian generic pharmaceuticals
利用1994-1997年加拿大处方药数据，发现首个进入市场的仿制药能获得约30%的持久市场份额优势，这对品牌药企发行伪仿制药的政策有重要启示。
This paper uses pooled cross-section data on Canadian ethical drug sales to examine the effect of entry timing on sales of generic drugs. The data is for all drugs for which the first generic competitor entered during the years 1994-1997. It is found that the first generic entrant has a lasting competitive advantage: being first into the market appears to lead to an increase of around 30% in market share (among generics) over a period of at least 4 years. This finding has considerable implications for the current policy of allowing brandname drug companies to issue pseudo-generic equivalents as a preemptive strike against true generic competitors.